Skip to main content

Advertisement

Table 3 Liver dysfunction and UGT1A1/1A9 polymorphisms

From: Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib

Liver test Grades 2-4 UGT1A1 UGT1A9 I399C > T
   Poor metabolizers Extensive metabolizers P-value C/T + T/T C/C P-value
ALT No 3 41 0.359 39 4 0.111
Yes 1 4 3 2
AST No 3 44 0.158 41 5 0.237
Yes 1 1 1 1
T.Bil No 1 35 0.052 34 2 0.028
Yes 3 10 8 4
Nilotinib C0 Median 687.6 1042.0 0.577 977.5 644.0 0.685
  Range (25–75) (336.1-1906.6) (614.9-1472.8)   (544.0-1473.0) (623.0-2292.0)  
  1. Poor metabolizers, UGT1A1 *6/*28, *27/*28, or *28/*28; Extensive metabolizers, UGT1A1 *1/*1, *1/*6, *1/*27, or *1/*28; C0, trough concentration.